Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma

8 Jan 2020

Abstract excerpt

The expression of p16/CDKN2A, the second most commonly inactivated tumour suppressor gene in cancer, is lost in the majority of chordomas. However, the mechanism(s) leading to its inactivation and contribution to disease progression have only been partially addressed using small patient cohorts. We studied 384 chordoma samples from 320 patients by immunohistochemistry and found that p16 protein was lost in 53% of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Tumor Diagnosis and Treatments
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31916407
DOI: 10.1002/cjp2.156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordomaPMID 31916407Read ↗

Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisationSemantic proximity Read ↗

Recurrent Chromosomal Copy Number Alterations in Sporadic ChordomasSemantic proximity Read ↗

Genomic aberrations frequently alter chromatin regulatory genes in chordoma.Semantic proximity Read ↗

Dysregulated Epigenetics of Chordoma: Prognostic Markers and Therapeutic TargetsSemantic proximity Read ↗

Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical RelevanceSemantic proximity Read ↗

Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencingSemantic proximity Read ↗

Chordoma Characterization of Significant Changes of the DNA Methylation PatternSemantic proximity Read ↗

Chordoma: Genetics and Contemporary Management.Semantic proximity Read ↗

Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.Semantic proximity Read ↗

Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomasSemantic proximity Read ↗

From Histology to Multi-Omics: Review of Chordoma Classification and Its Clinical ImplicationsSemantic proximity Read ↗

Epigenetic deregulations in chordomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.